A Genetic Locus within the FMN1/GREM1 Gene Region Interacts with Body Mass Index in Colorectal Cancer Risk

Grants

Funding Acknowledgements

EK. Aglago's associateship was supported by a Cancer Research UK (CRUK) grant awarded to K.K. Tsilidis (PPRCPJT\100005) . GECCO: NCI, NIH, U.S. Department of Health and Human Services (U01 CA137088, R01 CA059045, U01 CA164930, R01201407) . Genotyping/Sequencing services were provided by the Center for Inherited Disease Research (CIDR) contract number HHSN268201700006I and HHSN268201200008I. This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA015704. Scientific Computing Infrastructure at Fred Hutchinson Cancer Center funded by ORIP grant S10OD028685. The ATBC Study is supported by the Intramural Research Program of the U.S. NCI, NIH, Department of Health and Human Services. CLUE II funding was from the NCI (U01 CA86308, Early Detection Research Network; P30 CA006973) , National Institute on Aging (U01 AG18033) , and the American Institute for Cancer Research. Maryland Cancer Registry (MCR) : Cancer data was provided by the Maryland Cancer Registry, Center for Cancer Prevention and Control, Maryland Department of Health, with funding from the State of Maryland and the Maryland Cigarette Restitution Fund. The collection and availability of cancer registry data is also supported by the Cooperative Agreement NU58DP006333, funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services. The Colon Cancer Family Registry (CCFR, www.coloncfr.org) is supported in part by funding from the NCI, NIH (award U01 CA167551) . Support for case ascertainment was provided in part from the Surveillance, Epidemiology, and End Results (SEER) Program and the following U.S. state cancer registries: AZ, CO, MN, NC, NH; and by the Victoria Cancer Registry (Australia) and Ontario Cancer Registry (Canada) . The CCFR Set-1 (Illumina 1M/1M-Duo) and Set-2 (Illumina Omni1-Quad) scans were supported by NIH awards U01 CA122839 and R01 CA143247 (to G. Casey) . The CCFR Set-3 (Affymetrix Axiom CORECT Set array) was supported by NIH award U19 CA148107 and R01 CA81488 (to S.B. Gruber) . The CCFR Set-4 (Illumina OncoArray 600K SNP array) was supported by NIH award U19 CA148107 (to S.B. Gruber) and by the Center for Inherited Disease Research (CIDR) , which is funded by the NIH to the Johns Hopkins University, contract number HHSN268201200008I. Additional funding for the OFCCR/ARCTIC was through award GL201-043 from the Ontario Research Fund, award 112746 from the Canadian Institutes of Health Research, through a Cancer Risk Evaluation (CaRE) Program grant from the Canadian Cancer Society (to S. Gallinger) , and through generous support from the Ontario Ministry of Research and Innovation. The SFCCR Illumina HumanCytoSNP array was supported in part through NCI/NIH awards U01/U24 CA074794 and R01 CA076366 (to P.A. Newcomb) . The content of this manuscript does not necessarily reflect the views or policies of the NCI, NIH or any of the collaborating centers in the Colon Cancer Family Registry (CCFR) , nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government, any cancer registry, or the CCFR. Colorectal Cancer Transdisciplinary (CORECT) Study: The CORECT Study was supported by the NCI/NIH, U.S. Department of Health and Human Services (grant numbers U19 CA148107, R01 CA81488, P30 CA014089, R01 CA197350, P01 CA196569, R01 CA201407) and National Institutes of Environmental Health Sciences, NIH (grant number T32 ES013678) . CORSA: The CORSA study was funded by Austrian Research Funding Agency (FFG) BRIDGE (grant 829675 to Andrea Gsur) , the "Herzfelder'sche Familienstiftung" (grant to Andrea Gsur) , and was supported by COST Action BM 1206. CPS-II: The American Cancer Society funds the creation, maintenance, and updating of the Cancer Prevention Study-II (CPS-II) cohort. This study was con-ducted with Institutional Review Board approval. CRCGEN: Colorectal Cancer Genetics & amp; Genomics, Spanish study was sup-ported by Instituto de Salud Carlos III, co-funded by FEDER funds-a way to build Europe- (grants PI14-613 and PI09-1286) , Agency for Management of University and Research Grants (AGAUR) of the Catalan Government (grant 2017SGR723) , and Junta de Castilla y Leon (grant LE22A10-2) . Sample collection of this work was supported by the Xarxa de Bancs de Tumors de Catalunya sponsored by Pla Director d'Oncologia de Catalunya (XBTC) , Plataforma Bio-bancos PT13/0010/0013 and ICOBIOBANC, sponsored by the Catalan Institute of Oncology. Czech Republic CCS: This work was supported by the Grant Agency of the Czech Republic (18-09709S, 20-03997S) , by the Grant Agency of the Ministry of Health of the Czech Republic (grants AZV NV18/03/00199 and AZV NV19-09-00237) , and Charles University grants Unce/Med/006 and Progress Q28/LF1. DACHS: This work was supported by the German Research Council (BR 1704/6-1, BR 1704/6-3, BR 1704/6-4, CH 117/1-1, HO 5117/2-1, HE 5998/2-1, KL 2354/3-1, RO 2270/8-1, and BR 1704/17-1) , the Interdisciplinary Research Program of the National Center for Tumor Diseases (NCT) , Germany, and the German Federal Ministry of Education and Research (01KH0404, 01ER0814, 01ER0815, 01ER1505A, and 01ER1505B) . DALS: NIH (R01 CA48998 to M.L. Slattery) . EDRN: This work is funded and supported by the NCI, EDRN Grant (U01 CA 84968-06) . EPIC: The coordination of EPIC is financially supported by International Agency for Research on Cancer (IARC) and also by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, which has additional infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC) . The national cohorts are supported by Danish Cancer Society (Denmark) ; Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Generale de l'Education Nationale, Institut National de la Santeet de la Recherche Medicale (INSERM) (France) ; German Cancer Aid, German Cancer Research Center (DKFZ) , German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE) , Federal Ministry of Education and Research (BMBF; Germany) ; Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Compagnia di SanPaolo and National Research Council (Italy) ; Dutch Ministry of Public Health, Welfare and Sports (VWS) , Netherlands Cancer Registry (NKR) , LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland) , World Cancer Research Fund (WCRF) , Statistics Netherlands (The Netherlands) ; Health Research Fund (FIS) -Instituto de Salud Carlos III (ISCIII) , Regional Governments of Andalucia, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology (ICO; Spain) ; Swedish Cancer Society, Swedish Research Council and County Councils of Skane and Vaesterbotten (Sweden) ; Cancer Research UK (14136 to EPIC-Norfolk; C8221/A29017 to EPIC-Oxford) , Medical Research Council (1000143 to EPIC-Norfolk; MR/M012190/1 to EPIC-Oxford, United Kingdom) . ESTHER/VERDI. This work was supported by grants from the Baden-Wurttemberg Ministry of Science, Research and Arts and the German Cancer Aid. Harvard cohorts: HPFS is supported by the NIH (P01 CA055075, UM1 CA167552, U01 CA167552, R01 CA137178, R01 CA151993, and R35 CA197735) , NHS by the NIH (P01 CA087969, UM1 CA186107, R01 CA137178, R01 CA151993, and R35 CA197735) , and PHS by the NIH (R01 CA042182) . Hawaii Adenoma Study: NCI grants R01 CA72520. Kentucky: This work was supported by the following grant support: Clinical Investigator Award from Damon Runyon Cancer Research Foundation (CI-8) ; NCI R01CA136726. LCCS: The Leeds Colorectal Cancer Study was funded by the Food Standards Agency and Cancer Research UK Programme Award (C588/A19167) . MCCS cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian NHMRC grants 509348, 209057, 251553, and 504711 and by infrastructure provided by Cancer Council Victoria. Cases and their vital status were ascertained through the Victorian Cancer Registry (VCR) and the Australian Institute of Health and Welfare (AIHW) , including the National Death Index and the Australian Cancer Database. MEC: NIH (R37 CA54281, P01 CA033619, and R01 CA063464) . MECC: This work was supported by the NIH, U.S. Department of Health and Human Services (R01 CA81488, R01 CA197350) . NCCCS I & amp; II: The authors acknowledge funding support for this project from the NIH, R01 CA66635 and P30 DK034987. NFCCR: This work was supported by an Interdisciplinary Health Research Team award from the Canadian Institutes of Health Research (CRT 43821) ; the NIH, U.S. Department of Health and Human Serivces (U01 CA74783) ; and NCI of Canada grants (18223 and 18226) . The authors wish to acknowledge the contribution of Alexandre Belisle and the genotyping team of the McGill University and Genome Quebec Innovation Centre, Montreal, Canada, for genotyping the Sequenom panel in the NFCCR samples. Funding was provided to Michael O. Woods by the Canadian Cancer Society Research Institute. PLCO: Intramural Research Program of the Division of Cancer Epidemiology and Genetics and supported by contracts from the Division of Cancer Prevention, NCI, NIH, DHHS. Funding was provided by NIH, Genes, Environment and Health Initiative (GEI) Z01 CP 010200, NIH U01 HG004446, and NIH GEI U01 HG 004438. SELECT: Research reported in this publication was supported in part by the NCI of the NIH under award numbers U10 CA37429 (CD Blanke) and UM1 CA182883 (CM Tangen/IM Thompson) . The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. SMS: This work was supported by the NCI (grant P01 CA074184 to J.D. Potter and P.A. Newcomb, grants R01 CA097325, R03 CA153323, and K05 CA152715 to P.A. Newcomb, and the National Center for Advancing Translational Sciences at the NIH (grant KL2 TR000421) REACH: This work was supported by the NCI (grant P01 CA074184 to J.D. Potter and P.A. Newcomb, grants R01 CA097325, R03 CA153323, and K05 CA152715 to P.A. Newcomb, and the National Center for Advancing Translational Sciences at the NIH (grant KL2 TR000421 to A.N.B.-H.) UK Biobank: This research has been conducted using the UK Biobank Resource under Application Number 8614 VITAL: NIH (K05 CA154337) . WHI: The WHI program is funded by the National Heart, Lung, and Blood Institute, NIH, U.S. Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C. CCFR: The Colon CFR graciously thanks the generous contributions of their study participants, dedication of study staff, and the financial support from the U.S. NCI, without which this important registry would not exist. The authors would like to thank the study participants and staff of the Seattle Colon Cancer Family Registry and the Hormones and Colon Cancer study (CORE Studies) . CLUE II: The authors thank the participants of Clue II and appreciate the continued efforts of the staff at the Johns Hopkins George W. Comstock Center for Public Health Research and Prevention in the conduct of the Clue II Cohort Study. CORSA: The authors kindly thank all individuals who agreed to participate in the CORSA study. Furthermore, the authors thank all cooperating physicians and students and the Biobank Graz of the Medical University of Graz. CPS-II: The authors thank the CPS-II participants and Study Management Group for their invaluable contributions to this research. The authors would also like to acknowledge the contribution to this study from central cancer registries supported through the Centers for Disease Control and Prevention National Program of Cancer Registries, and cancer registries supported by the NCI Surveillance Epidemiology and End Results program. Czech Republic CCS: The authors are thankful to all clinicians in major hospitals in the Czech Republic, without whom the study would not be practicable. The authors are also sincerely grateful to all patients participating in this study. DACHS: The authors thank all participants and cooperating clinicians, and everyone who provided excellent technical assistance. EDRN: The authors acknowledge all contributors to the development of the resource at University of Pittsburgh School of Medicine, Department of Gastroenterology, Department of Pathology, Hepatology and Nutrition and Biomedical Informatics. EPIC: Where authors are identified as personnel of the International Agency for Research on Cancer/WHO, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer/WHO. Harvard cohorts (HPFS, NHS, PHS) : The study protocol was approved by the Institutional Review Boards of the Brigham and Women's Hospital and Harvard T.H. Chan School of Public Health, and those of participating registries as required. The authors acknowledge Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital as home of the NHS. The authors would like to acknowledge the contribution to this study from central cancer registries supported through the Centers for Disease Control and Prevention's National Program of Cancer Registries (NPCR) and/or the NCI's Surveillance, Epidemiology, and End Results (SEER) Program. Central registries may also be supported by state agencies, universities, and cancer centers. Participating central cancer registries include the following: Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Indiana, Iowa, Kentucky, Louisiana, Massachusetts, Maine, Maryland, Michigan, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, Seattle SEER Registry, South Carolina, Tennessee, Texas, Utah, Virginia, West Virginia, Wyoming. The authors assume full responsibility for analyses and inter-pretation of these data. Kentucky: The authors would like to acknowledge the staff at the Kentucky Cancer Registry. LCCS: The authors acknowledge the contributions of Jennifer Barrett, Robin Waxman, Gillian Smith, and Emma Northwood in conducting this study. NCCCS I & amp; II: The authors would like to thank the study participants and the NC Colorectal Cancer Study staff. PLCO: The authors thank the PLCO Cancer Screening Trial screening center investigators and the staff from Information Management Services Inc and Westat Inc. Most importantly, the authors thank the study participants for their contributions that made this study possible. Cancer incidence data have been provided by the District of Columbia Cancer Registry, Georgia Cancer Registry, Hawaii Cancer Registry, Minnesota Cancer Surveillance System, Missouri Cancer Registry, Nevada Central Cancer Registry, Pennsylvania Cancer Registry, Texas Cancer Registry, Virginia Cancer Registry, and Wisconsin Cancer Reporting System. All are supported in part by funds from the Center for Disease Control and Prevention, National Program for Central Registries, local states or by the NCI, Surveillance, Epidemiology, and End Results program. The results reported here and the conclusions derived are the sole responsibility of the authors. SELECT: The authors thank the research and clinical staff at the sites that parti-cipated on SELECT study, without whom the trial would not have been successful. The authors are also grateful to the 35,533 dedicated men who participated in SELECT. WHI: The authors thank the WHI investigators and staff for their dedication, and the study participants for making the program possible. A full listing of WHI investigators can be found at: http:// www.whi.org/researchers/Documents%20% 20Write%20a%20Paper/WHI%20Investigator%20Short%20List.pdf. The publication costs of this article were defrayed in part by the payment of publication fees. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.